SCHEMBL9480262

SCHEMBL9480262

CCC(c1ccccc1)C(O)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 6/20 0.61
SLC6A3 Q01959 6/20 0.61
SLC6A4 P31645 5/20 0.61
LMNA P02545 3/20 0.58
HKDC1 Q2TB90 1/20 0.55
AOC3 Q16853 2/20 0.53
CYP3A4 P08684 3/20 0.53
CYP2D6 P10635 3/20 0.53
ADRA2C P18825 2/20 0.52
CHRM2 P08172 2/20 0.52
ADRA1A P35348 2/20 0.52
CYP2C9 P11712 2/20 0.52
ALOX15 P16050 2/20 0.52
CYP2C19 P33261 2/20 0.52
RGS12 O14924 1/20 0.52
GLA P06280 1/20 0.52
PKM P14618 1/20 0.52
TSHR P16473 1/20 0.52
ALOX12 P18054 1/20 0.52
NFKB1 P19838 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12512912 1.00 SLC6A2 (0.61) SLC6A2SLC6A3SLC6A4LMNAHKDC1
SCHEMBL6939841 0.84 LMNA (0.60) SLC6A2SLC6A3SLC6A4LMNAAOC3
SCHEMBL18087746 0.84 LMNA (0.60) SLC6A2SLC6A3SLC6A4LMNAAOC3
SCHEMBL4071581 0.83 HKDC1 (0.65) SLC6A2SLC6A3SLC6A4LMNAHKDC1
SCHEMBL873376 0.82 LMNA (0.58) SLC6A2SLC6A3SLC6A4LMNAHKDC1
SCHEMBL18901666 0.82 LMNA (0.58) SLC6A2SLC6A3SLC6A4LMNAHKDC1
SCHEMBL10794618 0.82 LMNA (0.58) SLC6A2SLC6A3SLC6A4LMNAHKDC1
SCHEMBL1292631 0.82 LMNA (0.58) SLC6A2SLC6A3SLC6A4LMNAHKDC1
SCHEMBL17892871 0.82 LMNA (0.58) SLC6A2SLC6A3SLC6A4LMNAHKDC1
SCHEMBL4107117 0.82 LMNA (0.58) SLC6A2SLC6A3SLC6A4LMNAHKDC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110144139-B Zinc oxide-based nanoparticle ink and photoelectric device 纳晶科技股份有限公司 2022-01-18 CN claimed
CN-110144139-B Zinc oxide-based nanoparticle ink and photoelectric device 纳晶科技股份有限公司 2022-01-18 CN disclosed
US-8309552-B2 Immunomodulating heterocyclic compounds MEDIGENE AG (DE) 2012-11-13 US disclosed
US-20090312334-A1 Immunomodulating Heterocyclic Compounds MEDIGENE LIMITED (GB) 2009-12-17 US disclosed
EP-0247381-B1 5-FLUROROURACIL DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1993-08-04 EP disclosed
US-5047521-A Anticarcinogenic agents OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-09-10 US disclosed
EP-0247381-A2 5-flurorouracil derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1987-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312334-A1 Immunomodulating Heterocyclic Compounds CD40, CD40LG, NGFR SLC6A2 2376/4885SLC6A3 2484/4885SLC6A4 2486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.